HomeCompareBOVNF vs YUM

BOVNF vs YUM: Dividend Comparison 2026

BOVNF yields 60.82% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BOVNF wins by $571.1K in total portfolio value
10 years
BOVNF
BOVNF
● Live price
60.82%
Share price
$3.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$678.1K
Annual income
$160,128.39
Full BOVNF calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — BOVNF vs YUM

📍 BOVNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOVNFYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOVNF + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOVNF pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOVNF
Annual income on $10K today (after 15% tax)
$5,169.37/yr
After 10yr DRIP, annual income (after tax)
$136,109.13/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, BOVNF beats the other by $102,145.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOVNF + YUM for your $10,000?

BOVNF: 50%YUM: 50%
100% YUM50/50100% BOVNF
Portfolio after 10yr
$392.5K
Annual income
$100,042.85/yr
Blended yield
25.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

BOVNF
No analyst data
Altman Z
10.4
Piotroski
3/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOVNF buys
0
YUM buys
0
No recent congressional trades found for BOVNF or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOVNFYUM
Forward yield60.82%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$678.1K$107.0K
Annual income after 10y$160,128.39$39,957.33
Total dividends collected$563.7K$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: BOVNF vs YUM ($10,000, DRIP)

YearBOVNF PortfolioBOVNF Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$16,782$6,081.62$10,980$280.44+$5.8KBOVNF
2$27,495$9,538.25$12,185$435.72+$15.3KBOVNF
3$44,024$14,604.90$13,722$684.14+$30.3KBOVNF
4$68,961$21,855.37$15,773$1,090.14+$53.2KBOVNF
5$105,784$31,995.46$18,650$1,773.02+$87.1KBOVNF
6$159,058$45,869.04$22,921$2,966.37+$136.1KBOVNF
7$234,649$64,457.18$29,685$5,158.69+$205.0KBOVNF
8$339,944$88,869.20$41,216$9,453.02+$298.7KBOVNF
9$484,065$120,324.94$62,672$18,571.31+$421.4KBOVNF
10$678,078$160,128.39$107,016$39,957.33+$571.1KBOVNF

BOVNF vs YUM: Complete Analysis 2026

BOVNFStock

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

Full BOVNF Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this BOVNF vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOVNF vs SCHDBOVNF vs JEPIBOVNF vs OBOVNF vs KOBOVNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.